Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-08
2011-03-08
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S303000
Reexamination Certificate
active
07902179
ABSTRACT:
A pharmaceutical composition containing a heterocyclic compound of the formula (I)wherein each symbol is as defined in the specification, an isomer thereof, a solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient has a superior TNF-α production suppressing action. Accordingly, it is useful for the prophylaxis or treatment of various diseases caused by abnormal production of TNF-α.
REFERENCES:
patent: 4220646 (1980-09-01), Cotrel et al.
patent: 5883111 (1999-03-01), Naka et al.
patent: 5889032 (1999-03-01), Lohray et al.
patent: WO 94/27969 (1994-12-01), None
patent: 95/01980 (1995-01-01), None
patent: 96/12720 (1996-05-01), None
Merck Index, 9th Ed., 1976, p. FI-8.
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 212-228, in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons.
Gibson, “Increased gut permeability on Crohn's disease: is TNF the link?” Gut, 2004: 53, 1724-25.
Giamarellos-Bourboulis, et al., Effective Immunomodulatory Treatment ofEscherichia coliExperimental Sepsis with Thalidomide, Antimicrobial Agents and Chemotherapy, Aug. 2003, p. 2445-2449.
“Access to Anti- TNF-alpha Therapies for Adults with Inflammatory Arthritis,” Implementation of NICE Guidance on use of Anti-TNF-alpha Therapies for Adults with Rheumatoid Arthritis, Jun. 2005, pp. 1-8, the NICE Report.
Waldman, “Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases,” Arthritis Research & Therapy, vol. 6, No. 4, 2004, pp. 174-177.
Jimenez, “Infliximab in the Treatment of Severe Ulcerative Colitis,” Rev. esp. enfirmo Dig., vol. 2004, No. 2, Feb. 2004, 4 pages.
Odian et al (Schaum's Outline of Theory and Problems of General, Organic, and Biological Chemistry, p. 257, 1994).
Ask A Scientist (available online at http://www.newton.dep.anl.gov/askasci/chem00/chem00279.htm) accessed online on Feb. 10, 2009.
Williams et al (Principles of Medicinal Chemistry, 5th Edition, p. 59-61, published Feb. 2002).
STN Search Notes (Accession No. 1995:406626).
M. Helmy Elnagdi, “Reactions With β-Cyanoethylhydrazine-I”, Tetrahedron, vol. 30, pp. 2791-2796 1974.
Abdou Ahmed El-sayed, et al., “A New Route for the Preparation of Pyrazolo[4,3-c]pyridines”, Bulletin of the Chemical Society of Japan, vol. 46, 1801-1803, 1973.
J. Org. Chemi., vol. 24, pp. 963-966, 1959.
Edward C. Taylor, et al., The Reaction of Malononitrile with Substituted Hydrazines: New Routes to a-Aminoyrazolo[3,4-d]pyrimidines1.2, J. Am. Chem., vol. 81, pp. 2456-2464 1959.
M.D. Nair, et al., “Derivatives of2H-Pyrazolo[4,3-c]pyridines”, Indian J. Chem., vol. 5, pp. 464-466 1967.
M. Shimizu, et al.,Drug Metabolism Letters, vol. 1, pp. 77-79 (2007).
The Merck Index 12thEd., S. Budavari, et al. Eds., Merck & Co., Inc. Whitehouse Station, NJ 1996, pp. 178, 179, 1247, 1253 and 1677.
Chiba Akira
Chujoh Yoshitomo
Fujita Kohichi
Fukuda Syunsuke
Ikenoue Yuka
Ajinomoto Co. Inc.
Fetterolf Brandon J
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Ricci Craig
LandOfFree
Heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2737040